Table 2.

Clinical Outcomes

NOACs	sICH	Death*	Favorable Outcomes*†
Overall	20/462 (4.3% [2.7–6.4])	48/423 (11.3% [8.6–14.6])	164/375 (43.7% [38.8–48.8])
Dabigatran
Reversal with idarucizumab	2/44 (4.5% [0.8–13.4])	2/44 (4.5% [0.8–13.4])	34/43 (79.1% [65.4–89.3])
Without idarucizumab	8/108 (7.4% [3.5–13.4])	13/108 (12.0% [6.8–19.0])	29/74 (39.2% [28.6–50.5])

mRS indicates modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NOAC, non–vitamin K antagonist oral anticoagulants; and sICH, symptomatic intracranial hemorrhage.

^*At discharge or ≤3-month follow-up.

^†NIHSS, ≤1; mRS, 0–2; or improvement in NIHSS score, ≥8 points.